Akoya Biosciences Reveals Q4 and Full-Year Results with Insights
Financial Overview of Akoya Biosciences
Akoya Biosciences, Inc. (Nasdaq: AKYA), known for its innovations in spatial biology, has released its financial results for the fourth quarter and the full year ending December 31, 2024. The company faced a challenging market in 2024 but managed to grow in significant areas of its business.
Brian McKelligon, the CEO of Akoya, commented on the achievements made throughout the year, emphasizing that despite the obstacles in the life science tools market, which included reduced capital equipment purchases, the company successfully focused on enhancing gross margins and reducing operating costs. In fact, Akoya's installed base grew to 1,330 instruments, reflecting its strong market presence.
Fourth Quarter Financial Highlights
Revenues and Margins
During the fourth quarter of 2024, Akoya reported revenues of $21.3 million. This marks a decrease of 19.4% compared to the previous year's $26.5 million. The drop in revenue was largely due to a decline in instrument sales. On a positive note, gross margins improved to 67.4%, up from 62.7% the previous year, showcasing Akoya's commitment to operational efficiency, particularly through in-house manufacturing processes.
Efficient Operations
The company successfully reduced its operating expenses by 22.9%, coming in at $20.1 million for the quarter, compared to $26.1 million in the same period last year. This reduction is a result of improved operational leverage and better overall efficiencies.
Operating Losses
With a focus on continuous progress, Akoya reduced its operating loss from $9.4 million to $5.7 million, an improvement of 39.5%. As of December 31, 2024, the company had $35.0 million in cash, cash equivalents, and marketable securities, demonstrating a stable financial base moving forward.
Annual Financial Performance
Yearly Revenue Insights
For the entire year, Akoya’s revenue totaled $81.7 million, down from $96.6 million in 2023, which reflects a decrease of 15.5%. Despite this decline, Akoya's gross margin remained competitive at 58.6%. After adjusting for discontinued legacy products, non-GAAP adjusted gross margin stood at 61.1%.
Operating Efficiency Gains
Akoya's operating expenses totaled $94.6 million for the year, with non-GAAP adjusted expenses coming in at $88.6 million after removing impairment charges from restructuring efforts. The reduction in total expenses positions Akoya to better navigate future financial landscapes.
Strategic Milestones and Initiatives
Product Development and Market Impact
A notable achievement for Akoya was the announcement of its pending acquisition by Quanterix Corporation (Nasdaq: QTRX). This strategic partnership aims to establish an integrated solution for the detection of biological protein markers, enhancing Akoya’s product offerings while also expanding its presence in emerging markets such as neurobiology.
Innovative Collaborations
Throughout the year, Akoya advanced several clinical partnerships, notably with Acrivon and NeraCare. These collaborations focus on pushing the boundaries of clinical diagnostics and expanding the reach of spatial biology technologies.
Research Contributions and Future Outlook
Publication Growth
Akoya's technology has led to an impressive increase in research citations, with a total of 1,733 publications as of December 31, 2024. This marks a substantial rise of 49.4% from the prior year, reflecting the growing recognition of situational biology's importance in medical research.
Looking Ahead
In light of the upcoming acquisition, Akoya will forego hosting an earnings conference call or providing forward guidance at this time. However, plans for the future remain optimistic as the company aims to leverage its pioneering spatial biology solutions in numerous research domains.
Frequently Asked Questions
What are the key financial results for Akoya Biosciences in Q4 2024?
Akoya reported $21.3 million in revenue and achieved a gross margin of 67.4%. Operating expenses were reduced to $20.1 million, leading to a narrower operating loss of $5.7 million.
How has Akoya's overall performance changed compared to previous years?
Akoya's revenue decreased from $96.6 million to $81.7 million for the full year, but gross margins improved based on more efficient operations and product sales.
What strategic moves is Akoya making for growth?
Akoya is advancing a pending acquisition by Quanterix Corporation which will enhance its market reach and product offerings.
What collaborations did Akoya focus on in 2024?
Akoya collaborated with Acrivon and NeraCare on clinical partnerships to strengthen its diagnostic capabilities and expand into new markets.
How has Akoya's technology been received in research communities?
The technology has seen substantial growth in citations, with over 1,733 publications highlighting its increasing recognition in the field of spatial biology.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
